Global Leading Market Research Publisher QYResearch announces the release of its latest report “Diabetes Oral Medicine Dorzagliatin – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Diabetes Oral Medicine Dorzagliatin market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Diabetes Oral Medicine Dorzagliatin was estimated to be worth US320millionin2025andisprojectedtoreachUS320millionin2025andisprojectedtoreachUS1,450 million by 2032, growing at a CAGR of 24.0% from 2026 to 2032. For endocrinologists, diabetes care specialists, and pharmaceutical market strategists, the core business imperative lies in prescribing and developing dorzagliatin, a first-in-class glucokinase (GK) activator, that addresses the critical need for restoring glucose homeostasis in patients with type 2 diabetes (T2DM) by targeting the underlying glucose-sensing defect—unlike conventional oral antidiabetic agents that primarily manage downstream symptoms. Dorzagliatin acts on glucokinase targets in glucose storage and output organs including pancreatic islets, intestinal endocrine cells, and liver, to improve blood sugar homeostasis. Its dual-acting mechanism promotes insulin secretion from pancreatic β-cells in response to glucose stimulation, enhances glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells, and regulates hepatic glucose output via glycogen metabolism . This multi-organ synergistic action distinguishes dorzagliatin from existing oral hypoglycemic agents .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975552/diabetes-oral-medicine-dorzagliatin
The Diabetes Oral Medicine Dorzagliatin market is segmented as below:
Huamedicine (Hua Medicine)
Desano
Segment by Type
50mg
75mg
Others
Segment by Application
Hospital
Clinic
Laboratory
1. Market Drivers: Clinical Efficacy, Real-World Evidence, and Geographic Expansion
Several powerful forces are driving the dorzagliatin market:
First-in-class GKA mechanism targeting glucose homeostasis – Dorzagliatin (Huamingtang®, HuaTangNing®) activates glucokinase (GK), the body’s glucose sensor, to restore the set point for insulin secretion and hepatic glucose regulation. Phase 2/3 studies demonstrated significant reduction in HbA1c (1.2% reduction at 24 weeks) and improvements in β-cell function (HOMA-β, disposition index). A real-world study (BLOOM) involving 80 centers and 2,000 T2DM patients confirmed broad applicability and safety, with sustained HbA1c reduction from 8.3% to 7.5% at 6 months and TIR (time in range) improvement from 64.2% to 72.4% (p=0.033) . Randomized controlled trials showed dorzagliatin increased second-phase insulin secretion by 1.3-fold and enhanced β-cell glucose sensitivity in impaired glucose tolerance (IGT) population .
Strong commercial growth and market penetration – Following NMPA approval in September 2022, dorzagliatin has been included in China’s National Reimbursement Drug List (NRDL) since January 1, 2024. Over 200,000 patients in mainland China have received treatment. Sales of HuaTangNing® reached approximately 1.76 million packs in H1 2025 (108% YoY growth), with net sales of RMB217 million (112% YoY growth) . By year-end 2025, sales exceeded 4 million packs, generating RMB493 million (93% YoY growth), with total revenue exceeding RMB1.1 billion .
Hong Kong approval (March 2026) and international expansion – Dorzagliatin (MYHOMSIS®, HuaLingPian®) received Hong Kong approval under the “1+” drug regulatory innovation mechanism, marking the first chronic metabolic disease innovative drug approved under this pathway. This strategic milestone positions Hong Kong as the launchpad for Southeast Asian expansion (Singapore, Malaysia, Philippines, Vietnam) and provides a registered name for global commercial partnerships .
Recent market data (December 2025): According to Global Info Research analysis, 75mg dorzagliatin dominates with approximately 70% revenue share (standard adult dosing, twice daily). 50mg formulations hold 25% share (dosage adjustment, elderly). Distribution channels: hospitals (60%), clinics (30%), laboratories (10%). Asia-Pacific (China) accounts for 95% of market share, with expansion into Hong Kong (2026) and Southeast Asia driving future growth.
2. Product Specifications and Dosing
| Dosage Strength | Formulation | Dosing Regimen | Target Patient Population | Key Indications | Share |
|---|---|---|---|---|---|
| 50mg | Tablet | 50mg BID | Dose titration, elderly, mild renal impairment | Monotherapy, add-on to metformin | ~25% |
| 75mg | Tablet | 75mg BID | Standard adult T2DM patients | First-line monotherapy; combination with metformin | ~70% |
| Others | Combination / Clinical trial | Varies | Research settings | Investigational applications | ~5% |
Key specifications: Molecular mechanism (dual-acting allosteric GCK activator). Absorption (oral, Tmax ~2 hours). Half-life (6-8 hours). Route of elimination (CYP3A4 metabolism). Drug-drug interaction studies completed (empagliflozin, sitagliptin, itraconazole, rifampicin) . Indications (NMPA-approved: monotherapy for treatment-naive T2DM; combination with metformin for inadequate glycemic control). Clinical trial ongoing (Phase 2 for MODY-2/GCK-mutation diabetes; Phase 1 for pancreatic insufficiency cystic fibrosis). No dose adjustment required for mild-to-moderate renal impairment. Pregnancy, lactation, type 1 diabetes contraindicated.
Exclusive observation (Global Info Research analysis): Dorzagliatin’s unique dual-acting mechanism on both α- and β-cells differentiates it from existing DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists . Real-world studies suggest potential applications in diabetes prevention (IGT intervention), early T2DM treatment, and even diabetes remission—areas currently under investigation through the SENSITIZE study series in collaboration with the Chinese University of Hong Kong . The oral formulation offers convenience compared to injectable GLP-1 agonists.
User case – monotherapy for newly diagnosed T2DM (December 2025): A 52-year-old Chinese male patient with newly diagnosed T2DM (HbA1c 8.5%), BMI 26 kg/m², no prior medication. Initiated dorzagliatin 75mg BID. After 24 weeks, HbA1c reduced to 6.8%, with fasting plasma glucose normalization. No hypoglycemia reported.
User case – add-on to metformin (January 2026): A 60-year-old female patient with T2DM for 8 years, HbA1c 8.2% despite metformin 2000mg/day. Added dorzagliatin 75mg BID. At 3 months, HbA1c decreased to 7.1%. TIR (CGM) increased from 58% to 71%.
3. Key Challenges
Reimbursement and pricing – NRDL inclusion (2024) significantly improved patient access. However, out-of-pocket costs in non-reimbursed markets (Hong Kong, Southeast Asia) may limit adoption.
Physician awareness and prescribing preference – As a first-in-class GKA, dorzagliatin requires physician education on mechanism and positioning relative to established drug classes (metformin, SGLT2 inhibitors, DPP-4 inhibitors).
Technical difficulty – differentiation from existing classes: Dorzagliatin targets insulin secretion, GLP-1 secretion, and hepatic glucose output, offering potential benefits for β-cell preservation. Long-term cardiovascular outcomes data not yet available.
Technical development (October 2025): A phase 2 multi-ascending dose (MAD) study for second-generation GKA initiated in the US. Topline data expected mid-2026, with multinational corporation (MNC) partnership negotiations underway for global commercialization .
4. Competitive Landscape
Key players include: Hua Medicine (Huamedicine, China – developer and manufacturer, NMPA approval, NRDL inclusion), Desano (China – manufacturing collaboration). Commercial partnership with Bayer terminated effective January 1, 2025; Hua Medicine now fully independent in China commercialization . Hong Kong distribution partnerships TBD.
Regional dynamics: China (100% of current sales). Hong Kong approval (March 2026) initiates international expansion. Target markets: Singapore, Malaysia, Philippines, Vietnam under “one registration, multiple markets” strategy leveraging Hong Kong regulatory pathway . US development (Phase 2) for potential future entry.
5. Outlook
Dorzagliatin market will grow at 24.0% CAGR to US$1.45 billion by 2032, driven by NRDL expansion, Hong Kong/Southeast Asia launch, and increasing T2DM prevalence in Asia-Pacific. Technology trends: second-generation GKA, fixed-dose combinations (dorzagliatin + metformin), and label expansion to IGT/pre-diabetes populations.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
